CHA₂DS₂-VA Score for Atrial Fibrillation Stroke Risk
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–0
- Moderate Risk1–1
- High Risk2–9
The CHA₂DS₂-VA Score for Atrial Fibrillation Stroke Risk calculator is designed for bedside calculating stroke risk for patients with atrial fibrillation; similar to CHA₂DS₂-VASc Score but without considering sex in clinical practice. The resulting score directly guides clinician decision-making regarding initiating guideline-directed medical therapy, antithrombotic.
Clinical Guidelines & Evidence
Calculates stroke risk for patients with atrial fibrillation; similar to CHA₂DS₂-VASc Score but without considering sex. Simplified version recommended in 2024 ESC guidelines to remove complexity of gender-based scoring.
Clinical Indication
The CHA₂DS₂-VA Score for Atrial Fibrillation Stroke Risk is indicated for bedside clinical practice to support Calculates stroke risk for patients with atrial fibrillation; similar to CHA₂DS₂-VASc Score but without considering sex. Simplified version recommended in 2024 ESC guidelines to remove complexity of gender-based scoring.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.
Limitations & Contraindications
In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.
Clinical Pearls & Action Plan
Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines. Guideline pearl: Introduced in 2024 ESC guidelines to simplify CHA₂DS₂-VASc by removing sex category.
CHA₂DS₂-VA Score = C (1) + H (1) + A₂ (age ≥75: 2) + D (1) + S₂ (2) + V (1) + A (age 65-74: 1). Range: 0-8 points.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Patient age in years. <65 years (0 points), 65-74 years (1 point), ≥75 years (2 points)(years) |
| congestive_heart_failure | string | Yes | Congestive heart failure or left ventricular dysfunction (1 point if present) |
| hypertension | string | Yes | History of hypertension or currently on antihypertensive treatment (1 point if present) |
| diabetes_mellitus | string | Yes | Diabetes mellitus (1 point if present) |
| stroke_tia_thromboembolism | string | Yes | Prior stroke, TIA, or arterial thromboembolism (2 points if present) |
| vascular_disease | string | Yes | Vascular disease including myocardial infarction, peripheral artery disease, or aortic plaque (1 point if present) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Low Risk | Very low stroke risk |
| 1–1 | Moderate Risk | Low-moderate stroke risk |
| 2–9 | High Risk | High stroke risk |
Evidence-Based References (EBM)
- Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018;49(12):2933-2944.
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498.
- Romiti GF, Pastori D, Rivera-Caravaca JM, et al. Adherence to the 'Atrial Fibrillation Better Care' pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost. 2022;122(3):406-414.
- Boriani G, Ruff CT, Kuder JF, et al. Relationship between time to therapeutic anticoagulation and clinical outcomes in atrial fibrillation patients treated with warfarin. Europace. 2021;23(3):334-342.